Johnson & Johnson (JNJ)
Johnson & Johnson: Dividend Legend At A Discount
Johnson & Johnson's diversified revenue streams, significant presence in oncology and immunotherapy, and aggressive growth investments make it a strong defensive play. The company's low leverage, ample liquidity, and impressive free cash flow margin support its dividend sustainability and long-term growth. The stock is very attractively valued with an 18% potential upside.
Health Rounds: J&J drug helps delay multiple myeloma in high-risk patients
The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood cancer multiple myeloma for those at high risk, according to results from a trial presented at the American Society of Hematology meeting in San Diego.
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous trading day.
US FDA declines to approve injection form of J&J's lung cancer drug
The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for a type of lung cancer, the drugmaker said on Monday.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson Just Paid Investors: Here's How Much They Received
Johnson & Johnson (NYSE: JNJ) is rewarding its shareholders once again with a quarterly dividend of $1.24, payable on Tuesday, Dec.
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
In the most recent trading session, Johnson & Johnson (JNJ) closed at $150.47, indicating a -1.24% shift from the previous trading day.
J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids
Johnson & Johnson JNJ announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding
Johnson & Johnson offers investors an effective combination of dividend income and dividend growth, evidenced by its Dividend Yield [TTM] of 3.13% and 5-Year Dividend Growth Rate [CAGR] of 5.61%. The company from the Pharmaceuticals Industry, which has an Aaa credit rating from Moody's, can serve as a strategically important core-position within your dividend portfolio. Allocating the largest proportion of your dividend portfolio to Johnson & Johnson can position your portfolio for reduced volatility and help to decrease its overall risk level.
2 Very Healthy Dividend Stocks to Hold for Decades of Income
Checking a company's vital signs before investing in its stock for dividend income is essential. If the underlying company isn't financially healthy, its dividend probably won't last very long.
J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC
If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.
